About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

hope so, rather disappointed with lack of news

BIOTECHNOLOGY

Drugmakers arms races could spur biotech deals


BLOOMBERG NEWS


Tuesday, January 16, 2007

Vincent Aita of Kilkenny Capital Management says he picks biotechnology stocks on their potential as takeover targets. The strategy is paying off.

The number of biotech deals, including acquisitions and product alliances, rose 32 percent to 232 last year, according to data compiled by Bloomberg.

Vincent Aita Broker who manages about $200 million in health stocks expects to see more biotech acquisitions.

At least four of Aita's holdings, including Serono SA and Kos Pharmaceuticals Inc., were bought by bigger drug makers. Aita, who manages about $200 million in health stocks, is expecting more transactions in 2007.

"There is an escalating arms race,'' Aita said in last week at the JP Morgan Healthcare Conference in San Francisco. "There are more deals to be had.''

Pfizer Inc., the world's largest pharmaceuticals maker, and Merck & Co. might buy biotech companies to make up for a scarcity of experimental medicines and expiring patents for best-selling products.

On the shopping list are companies with experimental compounds as well as those with new drug-development science and technologies, investors at the conference said.

Last year, the number of biotech deals in North America, including acquisitions and joint ventures, increased from 175 in 2005, and the average premium rose to 33 percent from 23 percent, based on Bloomberg data.

More transactions and higher premiums are likely this year, said analysts, investors and company executives at the conference, the annual meeting where buyers and sellers gather and make deals.

"Premiums are going up,'' JP Morgan analyst Geoffrey Meacham said. "You're seeing a lot of bidding wars.''

Driving the trend are big pharmaceutical companies with billions in cash that need to acquire new drugs to continue to ensure growth.

Pfizer could lose almost half of its sales as a result of generic drug competition with products that have expiring patents.

Pfizer has entered at least six research partnerships since November.

Merck, the fourth-largest U.S. drug maker, could lose $3 billion in sales this year from its top-selling Zocor cholesterol pill because of competition from generic versions.

It signed 35 transactions last year, including the $1.1 billion purchase of Sirna Therapeutics Inc., which is developing drugs based on blocking genes involved in disease.

Merck aims to become "the best biotechnology company,'' CEO Richard Clark said. Its biotech deals totaled $1.4 billion in 2006.

"It's science and technology and potential companies; we're looking at all ends of the spectrum,'' Clark said. "Obviously, it's competitive.''

Eli Lilly & Co., which is offering $2.28 billion to buy its biotech partner Icos Corp., is spending $1.5 billion this decade on building its own biotechnology operations.

"The price of poker has definitely gone up,'' said John Lechleiter, Lilly's president and chief operating officer. "There are too few good assets and too many bidders.''

Amgen Inc., the world's biggest biotechnology company, and Biogen Idec Inc. also are considering acquisitions and alliances.

Since May, Biogen has bought three companies with a combined value exceeding $270 million to reduce its reliance on its biggest product, the multiple sclerosis treatment Avonex.

The company agreed this month to pay as much as $120 million for Syntonix Pharmaceuticals Inc., adding experimental treatments for hemophilia.

The pace of acquisitions "is the most active in our history,'' Biogen CEO James Mullen told investors at the conference.

Premiums over the market price of traded shares also are rising.

They ranged from 21 percent for Swiss drug maker Actelion Ltd.'s purchase of Cotherix Inc., a U.S. biotech company, to 170 percent for AnorMed Inc., which Genzyme Corp. took over in a bidding war with rival Millennium Pharmaceuticals Inc.

Genzyme's takeover of AnorMed was last year's first hostile bid by a biotechnology company, said Steven Burrill, CEO of Burrill & Co., a life-sciences investment adviser in San Francisco.

"Premiums are running 50 percent to 100 percent, which means the market is undervaluing the stocks," he said.

From the other side courtesy of Luckypicker


Luckypicker - 17 Jan'07 - 13:00 - 2916 of 2944

just to keep you up to date, I emailed Colin Tefler today

Dear Mr Tefler,

As an investor I would like to come to the AGM on Friday 2nd February, my shares are held in a dealing account, will a print out of my account be sufficient enough to attend the AGM, or do I need something else.

These are the questions I shall be asking yourselves so that your prepared in advance.

1) Where are we with regards to negotiations on ERX3722
2) Why was the market not informed last year that milestones were not going to be hit in the timescale mentioned in last years annual report - Mid 2006
3) Why was the company so keen to give a timescale on milestone payments last year but none this year.
4) What is the name of our product in OSI Pharma pipeline work
5) What is our position with regards to colorectal cancer as I believe reading from BB's news is expected on this
6) What is the company doing to get a broker note out.
7) Are the Directors confident enough with company as to buy a few more shares.
8) How many shares is the company expecting to have on the market in total until it becomes a revenue based company (3bln shares is going a bit far)
9) Is the company doing anything in the very very short term to stop further decline of the shareprice, now .0019p and people clearly still selling.
10) Was Zyzzgy Plc informed of the recent placing and no milestone in advance of the recent results as they sold in advance and at no profit.. I am very suspicious on this front as to why they sold.
11) Website, will this be recreated as its one of the worst I have seen, very difficult to find information, can I suggest a page for pipelines.

Sorry if this looks like a long list, but with the 50% decline in value of my investment I am clearly very very concerned as are many other private investors, not only this, the lack of information is clearly putting off any new potential investors.

Kind regards




Reply

"Colin Telfer"
17/01/2007 12:46
To
cc

Subject
RE: AGM

Dear Mr XXX

Thank you for drawing my attention to your concerns and for sharing in
advance the questions you intend to raise at the AGM.

To attend an AGM you would ordinarily be required to give your name at
the door on the day, which would be checked off against the company
register by an official from Capita Registrars.

As your shares are in a dealing account you are not named on the
register, and will need to bring a letter of representation from the
nominee account holder in order to attend and vote. If you do not have
such a letter of representation then EiRx may at its discretion permit
you to attend as a guest but you would not be able to speak or vote. As
you wish to raise questions for open discussion I would advise you to
request your nominee account holder to provide you with a letter of
representation on their headed paper. For further information you can
contact Capita on 0870 162 3100.

I look forward to meeting you and addressing your questions on the 2nd.

Regards,

Thanks Driver, Should be interesting ! :)

Cheers Driver some interesting questions - I e. mailed Colin this morning as well but had no reply yet.

Blimey down 15% i wonder whats going on ,oh well looks like ill have to write off that 5 grand stlg,thankgod i didnt have much in it.Probably news leaked we wiil find out last as always being mere PIs.

whats going on is we are being kept in the dark

Seems that way PH , very frustrating ,seemed like a tree shake earlier after all.Problem is general direction of this share is wrong way ,oh well guess we will all have to sit and wait ,AGM just round the corner.

One thought lads, is that the longer the price falls, the more attractive it becomes. The mm's will make sure they make money on this even if the company proves to be worthless. Therefore there are always going to be trading opportunities, but watch the spread.

Regaining old ground up 34%

ph
"we have a cure"

I see no news.

here it is driver..

Info on P53

http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33
http://news.independent.co.uk/uk/health_medical/article2183853.ece

http://news.independent.co.uk/uk/health_medical/article2183853.ece

compare it to this

http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33

Oncology mission for Scottish Life Sciences organisations
Date: 24 January 2007
Author: Neil McInnes
Ten of Scotlands leading companies and universities specialising in oncology research and development are participating in a trade mission to Massachusetts to develop closer links with global pharmaceutical companies based in the region.


The trip, which has been co-ordinated by Scottish Development Internationals life sciences team, will enable participants to meet with the US-based companies and identify how the work of Scottish based universities and companies could help advance the work of these companies in developing new treatments for cancer related illnesses.


Massachusetts has one of the largest concentrations of life sciences companies in the world with more than 280 companies and 30,000 employees working in the sector and an internationally renowned academic base. The Scottish delegation will be meeting some of the worlds leading pharmaceutical and biotechnology companies including Pfizer, Amgen and Genzyme to help open up new business opportunities.


The US companies will learn about Scotlands leading oncology centres of excellence, including the recently opened Beatson Institute at the University of Glasgows Garscube Estate and the University of Edinburghs Cancer Research Centre, which has been developed in partnership with Cancer Research UK. Leading Scottish companies such as Cyclacel Pharmaceuticals, CXR Biosciences and EiRx Therapeutics will also be attending to identify potential collaborative opportunities with the US-based firms.


Ian Leslie, team leader of the Scottish Development International Life Sciences team says: Boston and the wider Massachusetts state is regarded as one of the worlds leading life sciences locations and home to some of the worlds biggest pharmaceutical and biotech companies. Scotlands world class reputation in the oncology field has helped us get the foot in the door with these global firms and this trip will be hugely important in promoting Scotlands strengths in oncology research and developing new opportunities for collaborative working and new business opportunities for Scottish based organisations.


Scottish Biomedical, a drug discovery services company based in Glasgow, is one of the companies participating and hopes the trip will lead to developing new relationships overseas.


Simon Bury, Business Development Director of Scottish Biomedical, says: The US is obviously a very lucrative market for life sciences and Massachussets is a key market to target. This trip is enabling us to meet with a number of global companies and hopefully develop new relationships to capitalise on our existing contacts overseas.


Oncology is one of Scotlands leading areas of life sciences research and one which has significant commercial potential. There are almost fifty major research groups, centre of excellence and departments within eight Scottish Universities and Research Institutes, working to understand the causes of different cancers and developing new treatments. There is also a growing base of companies actively looking at drug discovery and development to develop new cancer therapeutics.


The full list of organisations participating in the trade mission are: Accuro Biologics Ltd; CXR Biosciences; Cyclacel Pharmaceuticals; EiRx Therapeutics PLC; Nexus Oncology; Scottish Biomedical; University of Aberdeen; University of Dundee; University of Edinburgh and University of Glasgow.

WONDER IF THE NEWS WILL BE THIS WEEK OR NEXT

Turning a cellular sentinel into a cancer killer
Similar Stories
Drug Therapy for GVHD Significantly Reduces Death
Using tai chi to fight degenerative nerve disease
Crucial Protein Role in Deadly Prion Spread
Quitting Smoking May Be Harder when Smoking during Pregnancy
Getting SAD is more than having bluesHoward Hughes Medical Institute researchers have developed two strategies to reactivate the p53 gene in mice, causing blood, bone and liver tumors to self destruct. The p53 protein is called the "guardian of the genome" because it triggers the suicide of cells with damaged DNA.

Inactivation of p53 can set the stage for the development of different types of cancer. The researchers' findings show for the first time that inactivating the p53 gene is necessary for maintaining tumors. While the researchers caution that cancers can mutate to circumvent p53 reactivation, they believe their findings offer ideas for new approaches to cancer therapy.

The research was carried out independently by two Howard Hughes Medical Institute (HHMI) research teams led by Tyler Jacks at the Massachusetts Institute of Technology and Scott Lowe at Cold Spring Harbor Laboratory. Both papers were published online January 24, 2007, in advance online publication articles in the journal Nature. Although researchers have long known that p53 inactivation plays a central role in the development of cancer, little was known about whether p53 inactivation played a role in maintaining cancers. And researchers were not sure whether switching p53 back on in tumor cells would have any therapeutic effect.

"It had been demonstrated that overexpressing p53 at very high levels could arrest or kill tumors, said Lowe. "But at such high levels, p53 might not be working through a physiological mechanism. So, it was an open question whether restoring the p53 pathway would have any anti-tumor effect." For one thing, the high mutation rate in cancers might enable a cancer to switch the p53 pathway back off, or to circumvent the pathway in some other fashion. For those reasons, researchers were not sure whether the pathway would be a useful therapeutic target.

To reactivate p53, Lowe and his colleagues used a genetic technique they had developed to induce an aggressive form of liver cancer in mice. Although they had inactivated p53 in the mice, they genetically engineered the mice so that they could reverse p53 inactivation by giving the animals the antibiotic doxycycline. They suppressed p53 protein levels by using RNA interference (RNAi) that had been modified so that RNAi could be switched off by the antibiotic. The RNA interference technology was developed in collaboration with HHMI investigator Gregory Hannon at Cold Spring Harbor Laboratory.

When the researchers reactivated p53 in the mice they found that the liver tumors completely disappeared. "This was quite surprising," said Lowe. "We were working with a very advanced, aggressive tumor, but when we reestablished p53, not only did it stop growing, it went away.

"But the second surpriseand perhaps the more scientifically interesting onewas why the tumor went away," said Lowe.

"We expected the tumor cells to undergo programmed cell death, or apoptosis. But instead, we saw evidence for a very different process that p53 also regulatessenescence, or growth arrest. What really excited us was evidence that this senescence somehow triggered the innate immune system to kill the tumor cells." Involvement of the innate immune system suggests there may be an unknown mechanism by which cancers can trigger the immune system, he said. Lowe and his colleagues are now exploring how the innate immune system might be enlisted against cancer.

Jacks's team used a different technique to reactivate p53 in lymphomas and sarcomas. In their experiments, the researchers produced mice whose cells did not have p53 activity. These mice were genetically engineered so that the drug tamoxifen could be used to switch on p53 activity.

"When we reactivated p53 in these mice, we saw two distinct tumor phenotypes," said Jacks. "In lymphomas the responses were rapid, extensive and were accompanied by the induction of apoptosis. In the sarcomas, the response was less rapid often less extensive and was not accompanied by apoptosis. Instead the cells underwent cell cycle arrest with features of senescence."

Jacks said that he and his colleagues found no evidence that restoring p53 affected normal cells. "That gives us a broader therapeutic window in which the cancer cells respond rapidly by one of these two mechanisms, whereas normal cells seem to tolerate reactivation of p53 quite well," he said.

In the December 29, 2006, issue of the journal Cell, Gerard Evan at the University of California at San Francisco reported that p53 restoration was effective in killing lymphoma tumor cells.

In a News & Views commentary published in Nature, Norman Sharpless and Ronald DePinho wrote that "these three papers provide reason for cautious optimism that reactivation of p53, and possibly of other tumour-suppressor genes, might be useful in treating certain cancers." However, they noted that Evan and his colleagues had seen rapid appearance of tumors that progressed despite p53 expression, indicating that cancers can mutate to deactivate the pathway or circumvent it.

Both Lowe and Jacks said they agreed that therapies aimed at reactivating p53 would still have to cope with the adaptability of cancers. "For any therapies based on these findings, you would have to imagine that sooner or later, resistance would develop," said Lowe. "And I think the challengewhich is true for any therapy where you can get resistanceis to come up with combination treatments that take out enough of the cancer cells early on that there aren't enough variants left to get around the p53 pathway."

Jacks added that "the main point is thatalthough there are differences between these mouse models and human cancerswe now can say with some confidence that established tumors are sensitive to p53 reactivation. There are already a number of treatment strategies being tested to restore p53 function, and these might well be expected to have therapeutic benefits."

Lowe emphasized that these new experimental techniques for reactivating p53 could also be applied to study the effects of other regulatory molecules on cancers. "We think we have a really powerful technology that could be generalized, not only to study tumor suppressors, but also molecules that might be important drivers of tumorigenesis, making them good drug targets," he said. "For these, we could do the converse experiment, letting the tumor develop and then using our technique to knock out the molecule and see whether the tumor goes away."

Jacks and his colleagues next plan to study the effects of p53 reactivation in other cancers. They hope to use the technology to understand why some cancers respond by undergoing apoptosis, while others undergo senescence.- Howard Hughes Medical Institute

next week is going to more than exciteing

PH let it just happen we already hold and constant long winded ramping is still driving people away not into ERX.
The sheer number of BB's makes anything said to be unreliable even without the drivel and personal conflicts.

NOTE JOHNSON AND JOHNSON HAS BEEN VISITING THE BB. WE MAY HAVE BAGGED A BIGGY

HERE IS THERE WEBSITE http://www.investor.jnj.com/calendar.cfm

J&J IP ADDRESS 148.177.129.213

VISITOR ANALYSIS
Referring Link No referring link
Host Name proxy2.be.jnj.com
IP Address 148.177.129.213
Country United States
Region New Jersey
City Raritan
ISP Johnson & Johnson
Returning Visits 18
Visit Length 1 min 51 secs
VISITOR SYSTEM SPECS
Browser MSIE 6.0
Operating System Windows 2000
Resolution Unknown
java script Disabled

Navigation Path

they vistited the AD fvn thread, it has an IP checker..

why are J&J from the USA visiting a UK BB..

buy as many as you can, they have visited the thread 18 times today and they visited yesterday as well, which is interesting as the sp rose 35% yesterday

yes I saw, looks like J&J def takeing a look for some reason. Is this part of the big plan.